# Genepath Diagnostics India Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genepath-diagnostics-india-private

- Industry: Biotechnology
- Headquarters: Pune, India
- Website: www.genepathdx.com
- Latest round: Series A (Jan 20, 2021)
- Investors on record: 2

## About

Genepath Diagnostics India Private Limited is a company focusing on molecular diagnostics and genomic testing services aimed at improving healthcare outcomes for infectious diseases, oncology, and genetic disorders.Founded in 2008 and headquartered in Pune, India, Genepath Diagnostics specializes in molecular diagnostics. The company has not undergone any significant changes in its business strategy since its inception. The founder, Nikhil Phadke, has a background in healthcare, and the current CEO is Nickhil Jakatdar. Genepath raised an undisclosed amount of Series A funding in January 2021, marking its first funding round.Genepath Diagnostics specializes in molecular diagnostic and genomic testing services, focusing on infectious diseases, oncology, and inherited genetic disorders. They offer custom-manufactured molecular and genomic reagents for research in the United States, as well as comprehensive assays and test kits for global markets. Since its inception in 2008, the company has processed nearly 200,000 clinical and research samples at its NABL-approved laboratory in Pune, India. Their products are utilized by over 100 laboratories and hospitals worldwide, addressing critical healthcare needs in diagnostic accuracy and patient management.In 2022, Genepath Diagnostics generated revenue of USD 2.79 mn, with an EBITDA loss of USD -624,351.7 for the same year. The company primarily generates revenue through B2B transactions with hospitals and laboratories, supplying diagnostic products and services tailored to various healthcare applications.Genepath Diagnostics is focusing on the development of new diagnostic products and expanding its market reach. The company aims to launch innovative testing solutions in the near future, targeting markets in Africa and Southeast Asia by 2023. The funding raised in January 2021 will be utilized to support these initiatives, including product development and market expansion strategies.

## Funding rounds

- Series A, Jan 20, 2021 — Saama Capital, Snow Leopard Ventures

## Investors

- Saama Capital (https://capitalatlas.ai/funds/saama-capital) — Series A
- Snow Leopard Ventures (https://capitalatlas.ai/funds/snow-leopard-ventures) — Series A